TYAN
25.2.2020 09:02:14 CET | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, is exhibiting their latest embedded motherboards optimized for the intelligent edge to service a wide range of vertical markets including security, industrial automation, communication and networking at Embedded World 2020 from February 25th ~27th , booth 2-311 in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005008/en/
“Based on the Intel® Xeon® E-2200 processor and 9th Generation Intel® Core™ i3/i5/i7 series processor, TYAN’s embedded motherboards demonstrate how standard-based platforms powered by robust processors efficiently meet the demands of data analytics at the IoT edge," said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. Hsu added, “With key features including compact form factors, a wide range of operating temperatures, and long product supply lifetime, our Tempest EX motherboards are the ideal choice to build up edge systems that can bridge compute, storage, and networking resources.”
TYAN’s embedded products provide 7-year supply lifecycle, wide operating temperature range of 0-55°C and optional EMC Class B certification on selected boards, which are highly required for most embedded IoT applications. The Tempest EX S5550-EX is equipped with up to four 1000Base-T LAN ports, three standard PCIe slots, eight SATA 6G ports, HD audio and display port interfaces in Micro-ATX form factor; the Tempest EX S5552-EX supports four 1000Base-T LAN ports, 8-port SAS 12G controller, four standard PCIe and an optional 32-bit legacy PCI slot in ATX form factor. Both S5550-EX and S5552-EX boards are well suited for industrial automation server applications. The Tempest EX S5555-EX with two display ports, one DVI-D port, and 7.1 channel high definition audio in Micro-ATX form factor is ideal for embedded workstation applications.
The Tempest EX S5557 features two 1000Base-T LAN ports, 12V DC power input and two display ports in Thin Mini-ITX form factor. The ultra-slim embedded motherboard is a perfect fit for IoT appliance deployment. Moreover, the Thunder CX GX38-B5550 is a 1U single-socket Intel Xeon E-2200 processor-based compact server for IoT and edge computing. Featuring up 4 DDR4 DIMM slots, up to 4 onboard GbE LAN ports, 1 PCIe x8 slot and two 3.5" internal SATA 6G drive bays within a 15” deep chassis, Thunder CX GX38-B5550 makes it a top choice for datacenters with space constraints.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005008/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom